Table 5 Adverse effects of MM-398.
From: Cancer nanomedicine: a review of recent success in drug delivery
|  | Nanoliposomal irinotecan plus fluorouracil and folinic acid combination therapy (n = 117) | Nanoliposomal irinotecan monotherapy (n = 147) | Fluorouracil and folinic acid control (n = 134) | |||
|---|---|---|---|---|---|---|
Any grade | Grades 3–4 | Any grade | Grades 3–4 | Any grade | Grades 3–4 | |
Diarrhoea | 69 (59%) | 15 (13%) | 103 (70%) | 31 (21%) | 35 (26%) | 6 (4%) |
Vomiting | 61 (52%) | 13 (11%) | 80 (54%) | 20 (14%) | 35 (26%) | 4 (3%) |
Nausea | 60 (51%) | 9 (8%) | 89 (61%) | 8 (5%) | 46 (34%) | 4 (3%) |
Decreased appetite | 52 (44%) | 5 (4%) | 72 (49%) | 13 (19%) | 43 (32%) | 3 (2%) |
Fatigue | 47 (40%) | 16 (14%) | 54 (37%) | 9 (6%) | 37 (28%) | 5 (4%) |
Neutropenia* | 46 (39%) | 32 (27%) | 37 (25%) | 22 (15%) | 7 (5%) | 2 (1%) |
Anaemia | 44 (38%) | 11 (9%) | 48 (33%) | 16 (11%) | 31 (23%) | 9 (7%) |
Hypokalemia | 14 (12%) | 4 (3%) | 32 (22%) | 17 (12%) | 12 (9%) | 3 (2%) |